Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 1/20 | 0.60 |
| ▸ | NPY2R | P49146 | 1/20 | 0.60 |
| ▸ | NPY4R | P50391 | 1/20 | 0.60 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.56 |
| ▸ | CHRNG | P07510 | 1/20 | 0.56 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.56 |
| ▸ | CHRND | Q07001 | 1/20 | 0.56 |
| ▸ | MME | P08473 | 1/20 | 0.56 |
| ▸ | MMP2 | P08253 | 1/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.54 |
| ▸ | ACE | P12821 | 3/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lysylphenylalanyltyrosine SCHEMBL30179304 | 1.00 | NPY1R (0.60) | NPY1RNPY2RNPY4RCHRNA1CHRNG | |
| Lysylphenylalanyltyrosine SCHEMBL4283579 | 1.00 | NPY1R (0.60) | NPY1RNPY2RNPY4RCHRNA1CHRNG | |
| Lysylphenylalanyltyrosine SCHEMBL14583994 | 1.00 | NPY1R (0.60) | NPY1RNPY2RNPY4RCHRNA1CHRNG | |
| Lysylphenylalanyltyrosine SCHEMBL4283566 | 1.00 | NPY1R (0.60) | NPY1RNPY2RNPY4RCHRNA1CHRNG | |
| SCHEMBL29577087 | 0.97 | NPY4R (0.59) | NPY1RNPY2RNPY4RCHRNA1CHRNG | |
| SCHEMBL29576811 | 0.97 | NPY4R (0.59) | NPY1RNPY2RNPY4RCHRNA1CHRNG | |
| SCHEMBL30179294 | 0.96 | NPY4R (0.63) | NPY1RNPY2RNPY4RCHRNA1CHRNG | |
| SCHEMBL15011504 | 0.94 | NPY4R (0.59) | NPY1RNPY2RNPY4RCHRNA1CHRNG | |
| SCHEMBL1373290 | 0.94 | NPY4R (0.59) | NPY1RNPY2RNPY4RCHRNA1CHRNG | |
| SCHEMBL1373292 | 0.94 | NPY4R (0.59) | NPY1RNPY2RNPY4RCHRNA1CHRNG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117025201-A | Preparation method of chiral silicon quantum dot for detecting concentration of peroxynitrite | 哈尔滨工程大学 | 2023-11-10 | — | — | CN | claimed |
| US-20250340591-A1 | COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASE CONTAINING NOVEL COMPOUND | ANYGEN CO LTD (KR) | 2025-11-06 | — | — | US | disclosed |
| EP-4317171-A1 | COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASE CONTAINING NOVEL COMPOUND | Anygen Co., Ltd. (KR) | 2024-02-07 | — | — | EP | disclosed |
| CN-117025201-A | Preparation method of chiral silicon quantum dot for detecting concentration of peroxynitrite | 哈尔滨工程大学 | 2023-11-10 | — | — | CN | disclosed |
| US-20230212222-A1 | COMPOSITION FOR ANTI-DIABETES AND ANTI-OBESITY COMPRISING NOVEL COMPOUND | ANYGEN CO., LTD. (KR) | 2023-07-06 | — | — | US | disclosed |
| WO-2023038464-A1 | COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASE CONTAINING NOVEL COMPOUND | 애니젠 주식회사 | 2023-03-16 | — | — | WO | disclosed |
| EP-4119570-A1 | COMPOSITION FOR ANTI-DIABETES AND ANTI-OBESITY COMPRISING NOVEL COMPOUND | Anygen Co., Ltd. (KR) | 2023-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250340591-A1 | COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASE CONTAINING NOVEL COMPOUND | GPR39, FABP2, GPR119 | NPY1R 1575/4885NPY2R 1800/4885NPY4R 1465/4885 |
| US-20230212222-A1 | COMPOSITION FOR ANTI-DIABETES AND ANTI-OBESITY COMPRISING NOVEL COMPOUND | GPR119, GPR39, FABP4 | NPY1R 361/4885NPY2R 535/4885NPY4R 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.